Literature DB >> 17449325

Common human Toll-like receptor 4 polymorphisms--role in susceptibility to respiratory syncytial virus infection and functional immunological relevance.

Stéphane C Paulus1, Aaron F Hirschfeld, Rachel E Victor, John Brunstein, Eva Thomas, Stuart E Turvey.   

Abstract

Evidence suggests that Toll-like receptor 4 (TLR4) contributes to immune recognition of respiratory syncytial virus (RSV). The TLR4 gene harbours a polymorphism-Asp299Gly-previously associated with reduced TLR4 signalling. To understand of how host genetic variation influences the outcome of RSV infection in children, we examined the association between the TLR4 299Gly allele and severe RSV disease. By genotyping 236 children with RSV infection and 219 healthy controls we found no association between the risk of severe RSV infection and Asp299Gly polymorphisms (P>0.05), and we demonstrate that the TLR4 Asp299Gly genotype does not influence susceptibility to either RSV serotype A or B (P>0.05). Finally, examining the functional impact of the TLR4 Asp299Gly polymorphism (n=58), we demonstrate that proinflammatory cytokine production following TLR4 activation was indistinguishable between homozygous (Asp/Asp) and heterozygous (Asp/Gly) subjects. We conclude that the Asp299Gly TLR4 polymorphism does not alter receptor function and does not influence the risk of severe RSV infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17449325     DOI: 10.1016/j.clim.2007.03.003

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  34 in total

Review 1.  TLR4 polymorphisms and disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Ali A Shah; Sheeba Murad Mall; Shazia Choudhary; Tahir Hussain; Iltaf Ahmed; Syed Fazal Jalil; Muhammad Imran Raza
Journal:  Inflamm Res       Date:  2012-01-26       Impact factor: 4.575

2.  Soluble forms of Toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-alpha secretion by macrophage-like cells.

Authors:  S L Zunt; L V Burton; L I Goldblatt; E E Dobbins; M Srinivasan
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

Review 4.  Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility.

Authors:  Mamoona Noreen; Muhammad Arshad
Journal:  Immunol Res       Date:  2015-06       Impact factor: 2.829

5.  Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation.

Authors:  Nicholas W Lukacs; Joost J Smit; Sumanta Mukherjee; Susan B Morris; Gabriel Nunez; Dennis M Lindell
Journal:  J Immunol       Date:  2010-07-12       Impact factor: 5.422

6.  Pathogen recognition receptor crosstalk in respiratory syncytial virus sensing: a host and cell type perspective.

Authors:  Nico Marr; Stuart E Turvey; Nathalie Grandvaux
Journal:  Trends Microbiol       Date:  2013-10-09       Impact factor: 17.079

Review 7.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

Review 8.  Human genetic factors and respiratory syncytial virus disease severity.

Authors:  Isao Miyairi; John P DeVincenzo
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

9.  TLR4 Asp299Gly and Thr399Ile polymorphisms: no impact on human immune responsiveness to LPS or respiratory syncytial virus.

Authors:  Renée N Douville; Yuriy Lissitsyn; Aaron F Hirschfeld; Allan B Becker; Anita L Kozyrskyj; Joel Liem; Nathalie Bastien; Yan Li; Rachel E Victor; Mehtab Sekhon; Stuart E Turvey; Kent T HayGlass
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

Review 10.  Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer.

Authors:  Andrei E Medvedev
Journal:  J Interferon Cytokine Res       Date:  2013-05-15       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.